Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro Significantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegeneration Reduces key pro-inflammatory markers, independent… Read More
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications VANCOUVER, BC & BOSTON,… Read More
WELL Health has added over 45,000 new primary care patient openings across its national clinic network, providing immediate relief in high-demand regions including Ontario, Alberta, and Manitoba. Patients would require… Read More
BC Cancer, in partnership with the UBC Faculty of Medicine, has rolled out the most advanced PET/CT scanner in the country – a next generation machine that provides fast imaging… Read More
Visceral leishmaniasis is a devastating yet treatable parasitic disease that affects thousands of people annually, particularly in low- and middle-income countries (LMICs). Despite existing treatments, barriers like high cost, complex… Read More
